3Q: Cost reduced, Revenue Generation Continues
gammaCore Becomes the 1st Approved Medical Device to Treat Coronavirus-related Breathing Difficulty
Q1 2020: Progressing Slowly but Steady
gammaCore Received Clearance for Prevention of Migraine
Q4 2019 Results: Lagged Commercial Success
Q3 2019: Revising Outlook After Slow Quarter
What do the recent developments mean for electroCore?
Soothing Investorsâ€™ Migraine a Bit?
Soothing Investors’ Migraine a Bit?
Choppy Waters for electroCore
Continuing Execution of the Redeployment Plan
Can the Reduced Cash Burn Calm Ragged Nerves?